Literature DB >> 7986206

Intrinsic cellular resistance to oxazaphosphorines exhibited by a human colon carcinoma cell line expressing relatively large amounts of a class-3 aldehyde dehydrogenase.

G K Rekha1, L Sreerama, N E Sladek.   

Abstract

A cultured human colon carcinoma cell line, viz. colon C, exhibiting intrinsic cellular resistance to mafosfamide mediated by relatively elevated levels of a cytosolic class-3 aldehyde dehydrogenase was identified. Colon C cells were found to be much less sensitive/more resistant (about 10-fold as judged by LC90 values) to mafosfamide than were two other cultured human colon carcinoma cell lines, viz. RCA and HCT 116b, and, as compared to the barely detectable aldehyde dehydrogenase activity (NADP-dependent enzyme-catalyzed oxidation of benzaldehyde to benzoic acid) in RCA and HCT 116b cells, that in colon C cells was about 200-fold greater. The three cell lines were equisensitive to phosphoramide mustard. Aldehyde dehydrogenase activity was confined to the cytosol in colon C cells (as well as in the other two cell lines) and, on the basis of its physical, immunological and catalytic characteristics, the operative enzyme was judged to be a Type-1 ALDH-3 identical to the Type-1 ALDH-3 expressed in methylcholanthrene-treated human breast adenocarcinoma MCF-7/0 cells and very nearly identical to the Type-1 ALDH-3 expressed in human normal stomach mucosa. Class-1 and class-2 aldehyde dehydrogenases were not found in these cells. The relative insensitivity to mafosfamide on the part of colon C cells was not observed when exposure to mafosfamide was in the presence of benzaldehyde or 4-(diethylamino)benzaldehyde, each a relatively good substrate for ALDH-3, whereas it was retained when exposure to mafosfamide was in the presence of acetaldehyde, a relatively poor substrate for this enzyme. Sensitivity to mafosfamide on the part of HCT 116b and RCA cells, and to phosphoramide mustard on the part of all three cell lines, was unaffected when drug exposure was in the presence of any of the three aldehydes. Together with earlier reports from our laboratory, these observations demonstrate that intrinsic, as well as stable and transient acquired, resistance to oxazaphosphorines, such as mafosfamide and cyclophosphamide, can be mediated by relatively increased levels of cytosolic class-3 aldehyde dehydrogenases.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7986206     DOI: 10.1016/0006-2952(94)90593-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  10 in total

1.  Aldehyde dehydrogenase 3B1 (ALDH3B1): immunohistochemical tissue distribution and cellular-specific localization in normal and cancerous human tissues.

Authors:  Satori A Marchitti; David J Orlicky; Chad Brocker; Vasilis Vasiliou
Journal:  J Histochem Cytochem       Date:  2010-09       Impact factor: 2.479

Review 2.  The role of non-P450 enzymes in drug oxidation.

Authors:  C Beedham
Journal:  Pharm World Sci       Date:  1997-12

3.  Development of selective inhibitors for human aldehyde dehydrogenase 3A1 (ALDH3A1) for the enhancement of cyclophosphamide cytotoxicity.

Authors:  Bibek Parajuli; Taxiarchis M Georgiadis; Melissa L Fishel; Thomas D Hurley
Journal:  Chembiochem       Date:  2014-03-21       Impact factor: 3.164

4.  A point mutation produced a class 3 aldehyde dehydrogenase with increased protective ability against the killing effect of cyclophosphamide.

Authors:  Kwok Ki Ho; Abhijit Mukhopadhyay; Yi Feng Li; Soma Mukhopadhyay; Henry Weiner
Journal:  Biochem Pharmacol       Date:  2008-07-04       Impact factor: 5.858

Review 5.  Aldehyde dehydrogenases in cellular responses to oxidative/electrophilic stress.

Authors:  Surendra Singh; Chad Brocker; Vindhya Koppaka; Ying Chen; Brian C Jackson; Akiko Matsumoto; David C Thompson; Vasilis Vasiliou
Journal:  Free Radic Biol Med       Date:  2012-11-27       Impact factor: 7.376

6.  Comprehensive proteomic profiling of aldehyde dehydrogenases in lung adenocarcinoma cell lines.

Authors:  Qing Zhang; Ayumu Taguchi; Mark Schliekelman; Chee-Hong Wong; Alice Chin; Rork Kuick; David E Misek; Samir Hanash
Journal:  Int J Proteomics       Date:  2011-10-29

7.  Selective ALDH3A1 inhibition by benzimidazole analogues increase mafosfamide sensitivity in cancer cells.

Authors:  Bibek Parajuli; Melissa L Fishel; Thomas D Hurley
Journal:  J Med Chem       Date:  2014-01-10       Impact factor: 7.446

8.  Stage-specific analysis of plasma protein profiles in ovarian cancer: Difference in-gel electrophoresis analysis of pooled clinical samples.

Authors:  Mark J Bailey; Kristy L Shield-Artin; Karen Oliva; Mustafa Ayhan; Simone Reisman; Gregory E Rice
Journal:  J Carcinog       Date:  2013-06-29

9.  ALDH1 is an immunohistochemical diagnostic marker for solitary fibrous tumours and haemangiopericytomas of the meninges emerging from gene profiling study.

Authors:  Corinne Bouvier; François Bertucci; Philippe Métellus; Pascal Finetti; André Maues de Paula; Fabien Forest; Karima Mokhtari; Catherine Miquel; Daniel Birnbaum; Alexandre Vasiljevic; Anne Jouvet; Jean-Michel Coindre; Anderson Loundou; Dominique Figarella-Branger
Journal:  Acta Neuropathol Commun       Date:  2013-05-09       Impact factor: 7.801

10.  A mechanically-induced colon cancer cell population shows increased metastatic potential.

Authors:  Xin Tang; Theresa B Kuhlenschmidt; Qian Li; Shahjahan Ali; Stephane Lezmi; Hong Chen; Melissa Pires-Alves; William W Laegreid; Taher A Saif; Mark S Kuhlenschmidt
Journal:  Mol Cancer       Date:  2014-05-29       Impact factor: 27.401

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.